These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30374417)

  • 41. Dextran-coupled deferoxamine improves outcome in a murine model of head injury.
    Panter SS; Braughler JM; Hall ED
    J Neurotrauma; 1992; 9(1):47-53. PubMed ID: 1377753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats.
    Jones G; Zeng L; Stiles WR; Park SH; Kang H; Choi HS; Kim J
    Nanomedicine (Lond); 2022 Sep; 17(22):1649-1662. PubMed ID: 36547231
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Iron Chelator Deferoxamine Alleviates Progression of Diabetic Nephropathy by Relieving Inflammation and Fibrosis in Rats.
    Feng Y; Jia L; Ma W; Tian C; Du H
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
    Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
    J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Localized deferoxamine injection augments vascularity and improves bony union in pathologic fracture healing after radiotherapy.
    Donneys A; Weiss DM; Deshpande SS; Ahsan S; Tchanque-Fossuo CN; Sarhaddi D; Levi B; Goldstein SA; Buchman SR
    Bone; 2013 Jan; 52(1):318-25. PubMed ID: 23085084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multifunctional Polymeric Micelles for Combining Chelation and Detection of Iron in Living Cells.
    Liu Z; Purro M; Qiao J; Xiong MP
    Adv Healthc Mater; 2017 Sep; 6(17):. PubMed ID: 28661064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.
    Liu Z; Qiao J; Nagy T; Xiong MP
    J Control Release; 2018 Aug; 283():84-93. PubMed ID: 29792889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
    Qadah T
    J Int Med Res; 2022 Dec; 50(12):3000605221143290. PubMed ID: 36562113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Calcium ion cross-linked sodium alginate hydrogels containing deferoxamine and copper nanoparticles for diabetic wound healing.
    Li S; Wang X; Chen J; Guo J; Yuan M; Wan G; Yan C; Li W; Machens HG; Rinkevich Y; Yang X; Song H; Chen Z
    Int J Biol Macromol; 2022 Mar; 202():657-670. PubMed ID: 35066024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus.
    Liu Z; Dumville JC; Hinchliffe RJ; Cullum N; Game F; Stubbs N; Sweeting M; Peinemann F
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010318. PubMed ID: 30328611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing.
    Brem H; Balledux J; Bloom T; Kerstein MD; Hollier L
    Arch Surg; 2000 Jun; 135(6):627-34. PubMed ID: 10843357
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Iron chelation therapy.
    Hershko CM; Link GM; Konijn AM; Cabantchik ZI
    Curr Hematol Rep; 2005 Mar; 4(2):110-6. PubMed ID: 15720959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Zn/Ga-DFO iron-chelating complex attenuates the inflammatory process in a mouse model of asthma.
    Bibi H; Vinokur V; Waisman D; Elenberg Y; Landesberg A; Faingersh A; Yadid M; Brod V; Pesin J; Berenshtein E; Eliashar R; Chevion M
    Redox Biol; 2014; 2():814-9. PubMed ID: 25009783
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
    Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR
    Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Iron Overload in Patients With Heavily Transfused Sickle Cell Disease-Correlation of Serum Ferritin With Cardiac T2
    Alkindi S; Panjwani V; Al-Rahbi S; Al-Saidi K; Pathare AV
    Front Med (Lausanne); 2021; 8():731102. PubMed ID: 34760898
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D; Ponka P; Baker E
    Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Excretion of iron in response to deferoxamine in sickle cell anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):659-62. PubMed ID: 633013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.